Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 401-420 , September 2006

Monogenic mineralocorticoid hypertension

  • Michael Stowasser, MBBS, FRACP, PhD (Associate Professor and Co-Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +61 7 32402694; Fax: +61 7 32402969.

References 

  1. Gordon RD, Klemm SA, Tunny TJ, et al. Primary aldosteronism: hypertension with a genetic basis. Lancet. 1992;340:159–161
  2. Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2854–2859
  3. Lim PO, Rodgers P, Cardale K, et al. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet. 1999;353:40
  4. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. The Journal of Clinical Endocrinology and Metabolism. 2004;89:1045–1050
  5. Young WF. Primary aldosteronism: a common and curable form of hypertension. Cardiology in Review. 1999;7:207–214
  6. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Archives of Internal Medicine. 1981;141:1589–1593
  7. Gordon RD, Stowasser M, Tunny TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clinical and Experimental Pharmacology and Physiology. 1994;21:315–318
  8. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. Journal of Molecular and Cellular Cardiology. 1993;25:563–575
  9. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997;95:1471–1478
  10. Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. The Journal of Clinical Endocrinology and Metabolism. 2005;90:5070–5076
  11. Gordon RD. Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension. 1986;8:93–102
  12. Kahle KT, Wilson FH, Lalioti M, et al. WNK kinases: molecular regulators of integrated epithelial ion transport. Current Opinion in Nephrology and Hypertension. 2004;13:557–562
  13. Tobin MD, Raleigh SM, Newhouse S, et al. Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation. 2005;112:3423–3429
  14. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Canadian Medical Association Journal. 1966;95:1109–1119
  15. Stowasser M, Gordon RD. Familial hyperaldosteronism. The Journal of Steroid Biochemistry and Molecular Biology. 2001;78:215–229
  16. Miura K, Yoshinaga K, Goto K, et al. A case of glucocorticoid-responsive hyperaldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1968;28:1807–1815
  17. Gordon RD, Gomez-Sanchez CE, Hamlet SM, et al. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. Journal of Hypertension. Supplement. 1987;5:S103–S106
  18. New MI, Peterson RE. A new form of congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 1967;27:300–305
  19. Fallo F, Sonino N, Armanini D, et al. A new family with dexamethasone-suppressible hyperaldosteronism: aldosterone unresponsiveness to angiotensin II. Clinical Endocrinology. 1985;22:777–785
  20. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–265
  21. Connell JM, Kenyon CJ, Corrie JE, et al. Dexamethasone-suppressible hyperaldosteronism. Adrenal transition cell hyperplasia?. Hypertension. 1986;8:669–676
  22. Woodland E, Tunny TJ, Hamlet SM, et al. Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism. Clinical and Experimental Pharmacology and Physiology. 1985;12:245–248
  23. Ganguly A, Grim CE, Weinberger MH. Anomalous postural aldosterone response in glucocorticoid-suppressible hyperaldosteronism. The New England Journal of Medicine. 1981;305:991–993
  24. Stowasser M, Gordon RD, Klemm SA, et al. Renin-aldosterone response to dexamethasone in glucocorticoid-suppressible hyperaldosteronism is altered by coexistent renal artery stenosis. The Journal of Clinical Endocrinology and Metabolism. 1993;77:800–804
  25. Wisgerhof M, Brown RD, Hogan MJ, et al. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1981;52:195–198
  26. Newton MA, Laragh JH. Effects of glucocorticoid administration on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1968;28:1014–1022
  27. Newton MA, Laragh JH. Effect of corticotropin on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1968;28:1006–1013
  28. Grim CE, Weinberger MH. Familial, dexamethasone-suppressible, normokalemic hyperaldosteronism. Pediatrics. 1980;65:597–604
  29. New MI, Peterson RE, Saenger P, et al. Evidence for an unidentified ACTH-induced steroid hormone causing hypertension. The Journal of Clinical Endocrinology and Metabolism. 1976;43:1283–1293
  30. Stowasser M, Gartside MG, Taylor WL, et al. In familial hyperaldosteronism type I, hybrid gene-induced aldosterone production dominates that induced by wild-type genes. The Journal of Clinical Endocrinology and Metabolism. 1997;82:3670–3676
  31. Ulick S, Chu MD. Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. Clinical and Experimental Hypertension. Part A, Theory and Practice. 1982;4:1771–1777
  32. Gomez-Sanchez CE, Montgomery M, Ganguly A, et al. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1984;59:1022–1024
  33. Ulick S, Chan CK, Gill JR, et al. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1990;71:1151–1157
  34. Hampf M, Dao NT, Hoan NT, et al. Unequal crossing-over between aldosterone synthase and 11beta-hydroxylase genes causes congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 2001;86:4445–4452
  35. Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties. Journal of Hypertension. 2000;18:1165–1176
  36. Litchfield WR, New MI, Coolidge C, et al. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1997;82:3570–3573
  37. Mulatero P, Veglio F, Pilon C, et al. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. The Journal of Clinical Endocrinology and Metabolism. 1998;83:2573–2575
  38. Stowasser M, Gartside MG, Gordon RD. A PCR-based method of screening individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I. Australian and New Zealand Journal of Medicine. 1997;27:685–690
  39. Jonsson JR, Klemm SA, Tunny TJ, et al. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochemical and Biophysical Research Communications. 1995;207:565–571
  40. Stowasser M, Huggard PR, Rossetti TR, et al. Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I. The Journal of Clinical Endocrinology and Metabolism. 1999;84:4031–4036
  41. Stowasser M, Bachmann AW, Huggard PR, et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2160–2166
  42. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids. 1995;60:48–51
  43. Rich GM, Ulick S, Cook S, et al. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Annals of Internal Medicine. 1992;116:813–820
  44. Jamieson A, Slutsker L, Inglis GC, et al. Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. Clinical Science (London). 1995;88:563–570
  45. Pascoe L, Curnow KM, Slutsker L, et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proceedings of the National Academy of Sciences of the United States of America. 1992;89:8327–8331
  46. Ganguly A. Primary aldosteronism. The New England Journal of Medicine. 1998;339:1828–1834
  47. Stowasser M, Bachmann AW, Huggard PR, et al. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. The Journal of Clinical Endocrinology and Metabolism. 2000;85:3313–3318
  48. Gordon RD, Stowasser M, Tunny TJ, et al. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clinical and Experimental Pharmacology and Physiology. 1991;18:283–286
  49. Stowasser M, Gordon RD, Tunny TJ, et al. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clinical and Experimental Pharmacology and Physiology. 1992;19:319–322
  50. Stowasser M, Gordon RD. Primary aldosteronism: from genesis to genetics. Trends in Endocrinology and Metabolism. 2003;14:310–317
  51. Fallo F, Veglio F, Mulatero P, et al. Genetic studies in familial aldosteronism not suppressible by dexamethasone. The Journal of Endocrine Genetics. 2000;1:159–164
  52. London N, Swales J, Hollinrake K, et al. Familial Conn's syndrome. Postgraduate Medical Journal. 1992;68:976–977
  53. Gordon RD, Stowasser M, Klemm SA, et al. Primary aldosteronism and other forms of mineralocorticoid hypertension. In:  Swales J editors. Textbook of Hypertension. London: Blackwell Scientific Publications; 1994;p. 865–892
  54. Takeda Y, Furukawa K, Inaba S, et al. Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1999;84:1633–1637
  55. Hampf M, Widimsky J, Bernhardt R. Aldosterone synthase gene in patients suffering from hyperaldosteronism. Endocrine Research. 1998;24:877–880
  56. Curnow KM, Mulatero P, Emeric-Blanchouin N, et al. The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. Nature Structural Biology. 1997;4:32–35
  57. Pilon C, Mulatero P, Barzon L, et al. Mutations in CYP11B1 gene converting 11beta-hydroxylase into an aldosterone-producing enzyme are not present in aldosterone-producing adenomas. The Journal of Clinical Endocrinology and Metabolism. 1999;84:4228–4231
  58. Klemm SA, Ballantine DM, Tunny TJ, et al. PCR-SSCP analysis of the angiotensin II type 1 receptor gene in patients with aldosterone-producing adenomas. Clinical and Experimental Pharmacology and Physiology. 1995;22:457–459
  59. Iida A, Blake K, Tunny T, et al. Allelic losses on chromosome band 11q13 in aldosterone-producing adrenal tumors. Genes Chromosomes and Cancer. 1995;12:73–75
  60. Gordon R, Gartside M, Tunny T, et al. Different allelic patterns at chromosome 11q13 in paired aldosterone-producing tumours and blood DNA. Clinical and Experimental Pharmacology and Physiology. 1996;23:594–596
  61. Ballantine DM, Klemm SA, Tunny TJ, et al. PCR-SSCP analysis of the p53 gene in tumours of the adrenal gland. Clinical and Experimental Pharmacology and Physiology. 1996;23:582–583
  62. Torpy DJ, Gordon RD, Lin JP, et al. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. The Journal of Clinical Endocrinology and Metabolism. 1998;83:3214–3218
  63. Torpy DJ, Stratakis CA, Gordon RD. Linkage analysis of familial hyperaldosteronism type II – absence of linkage to the gene encoding the angiotensin II receptor type 1. The Journal of Clinical Endocrinology and Metabolism. 1998;83:1046
  64. Lafferty AR, Torpy DJ, Stowasser M, et al. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). Journal of Medical Genetics. 2000;37:831–835
  65. Elphinstone MS, Gordon RD, So A, et al. Genomic structure of the human gene for protein kinase A regulatory subunit R1-beta (PRKAR1B) on 7p22: no evidence for mutations in familial hyperaldosteronism type II in a large affected kindred. Clinical Endocrinology. 2004;61:716–723
  66. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nature Genetics. 2000;26:89–92
  67. So A, Duffy DL, Gordon RD, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. Journal of Hypertension. 2005;23:1477–1484
  68. Warnock DG. Liddle syndrome: genetics and mechanisms of Na+ channel defects. The American Journal of the Medical Sciences. 2001;322:302–307
  69. Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. The Journal of Clinical Endocrinology and Metabolism. 1983;56:222–229
  70. White PC, Speiser PW. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinology and Metabolism Clinics of North America. 1994;23:325–339
  71. New MI. Inborn errors of adrenal steroidogenesis. Molecular and Cellular Endocrinology. 2003;211:75–83
  72. New MI. Polycystic ovarian disease and congenital and late-onset adrenal hyperplasia. Endocrinology and Metabolism Clinics of North America. 1988;17:637–648
  73. Geley S, Kapelari K, Johrer K, et al. CYP11B1 mutations causing congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. TheJournal of Clinical Endocrinology and Metabolism. 1996;81:2896–2901
  74. Krone N, Riepe FG, Gotze D, et al. Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: functional characterization of two novel point mutations and a three-base pair deletion in the CYP11B1 gene. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3724–3730
  75. Kater CE, Biglieri EG. Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinology and Metabolism Clinics of North America. 1994;23:341–357
  76. Biglieri EG, Herron MA, Brust N. 17-hydroxylation deficiency in man. The Journal of Clinical Investigation. 1966;45:1946–1954
  77. Rumsby G, Skinner C, Lee HA, et al. Combined 17 alpha-hydroxylase/17,20-lyase deficiency caused by heterozygous stop codons in the cytochrome P450 17 alpha-hydroxylase gene. Clinical Endocrinology. 1993;39:483–485
  78. Yanase T. 17 alpha-Hydroxylase/17,20-lyase defects. The Journal of Steroid Biochemistry and Molecular Biology. 1995;53:153–157
  79. Charmandari E, Kino T, Chrousos GP. Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms. Annals of the New York Academy of Sciences. 2004;1024:168–181
  80. Chrousos GP, Loriaux DL, Brandon D, et al. Primary cortisol resistance: a familial syndrome and an animal model. Journal of Steroid Biochemistry. 1983;19:567–575
  81. Vingerhoeds AC, Thijssen JH, Schwarz F. Spontaneous hypercortisolism without Cushing's syndrome. The Journal of Clinical Endocrinology and Metabolism. 1976;43:1128–1133
  82. Malchoff DM, Brufsky A, Reardon G, et al. A mutation of the glucocorticoid receptor in primary cortisol resistance. The Journal of Clinical Investigation. 1993;91:1918–1925
  83. Ruiz M, Lind U, Gafvels M, et al. Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clinical Endocrinology. 2001;55:363–371
  84. Charmandari E, Kino T, Ichijo T, et al. Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRalphaR477H and hGRalphaG679S associated with generalized glucocorticoid resistance. The Journal of Clinical Endocrinology and Metabolism. 2006;91:1535–1543
  85. Stewart PM, Corrie JE, Shackleton CH, et al. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. The Journal of Clinical Investigation. 1988;82:340–349
  86. Lavery GG, Ronconi V, Draper N, et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension. 2003;42:123–129
  87. Li A, Li KX, Marui S, et al. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. Journal of Hypertension. 1997;15:1397–1402
  88. Palermo M, Shackleton CH, Mantero F, et al. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology. 1996;45:605–611
  89. New MI, Wilson RC. Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:12790–12797
  90. Wilson RC, Krozowski ZS, Li K, et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. The Journal of Clinical Endocrinology and Metabolism. 1995;80:2263–2266
  91. Stewart PM, Krozowski ZS, Gupta A, et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet. 1996;347:88–91
  92. Mune T, Rogerson FM, Nikkila H, et al. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nature Genetics. 1995;10:394–399
  93. Mune T, White PC. Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension. 1996;27:1193–1199
  94. Li A, Tedde R, Krozowski ZS, et al. Molecular basis for hypertension in the ‘type II variant’ of apparent mineralocorticoid excess. American Journal of Human Genetics. 1998;63:370–379
  95. Ferrari P, Lovati E, Frey FJ. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. Journal of Hypertension. 2000;18:241–248
  96. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119–123
  97. Rafestin-Oblin ME, Souque A, Bocchi B, et al. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology. 2003;144:528–533
  98. Geller DS. A mineralocorticoid receptor mutation causing human hypertension. Current Opinion in Nephrology and Hypertension. 2001;10:661–665
  99. Zhang J, Simisky J, Tsai FT. A critical role of helix 3-helix 5 interaction in steroid hormone receptor function. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:2707–2712
  100. Liddle GW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Transations of the Association of American Physicians. 1963;26:199–213
  101. Findling JW, Raff H, Hansson JH, et al. Liddle's syndrome: prospective genetic screening and suppressed aldosterone secretion in an extended kindred. The Journal of Clinical Endocrinology and Metabolism. 1997;82:1071–1074
  102. Noblins M, Kleinknecht D, Dommergues JP, et al. Liddle syndrome (or pseudo-hyperaldosteronism). Long-term development and erythrocyte potassium flow study in 4 cases, Archives Françaises de Pédiatrie. 1992;49:685–691
  103. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79:407–414
  104. Hansson JH, Nelson-Williams C, Suzuki H, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nature Genetics. 1995;11:76–82
  105. Abriel H, Loffing J, Rebhun JF, et al. Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome. The Journal of Clinical Investigation. 1999;103:667–673
  106. Knight KK, Olson DR, Zhou R. Liddle's syndrome mutations increase Na+ transport through dual effects on epithelial Na+ channel surface expression and proteolytic cleavage. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:2805–2808
  107. Baker EH, Dong YB, Sagnella GA, et al. Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London. Lancet. 1998;351:1388–1392
  108. Rayner BL, Owen EP, King JA, et al. A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. Journal of Hypertension. 2003;21:921–926
  109. Persu A, Coscoy S, Houot AM, et al. Polymorphisms of the gamma subunit of the epithelial Na+ channel in essential hypertension. Journal of Hypertension. 1999;17:639–645

PII: S1521-690X(06)00055-8

doi: 10.1016/j.beem.2006.07.008

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 401-420 , September 2006

Article Tools